Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

Videos [1633]
News [6491]
Articles [98]
Editorials [4]
Conferences [184]
elearning [21]
Risk of serious and fatal adverse events with sorafenib use in patients with...
Dr Bishal Gyawali - Nagoya University, Nagoya, Japan
Risk of serious and fatal adverse events with sorafenib use in patients with solid cancers ( Dr Bishal Gyawali - Nagoya University, Nagoya, Japan )
12 Oct 2016
Combination of MEDI0680, an anti-PD-1 antibody, with durvalumab, an anti-PD-L1...
Dr Omid Hamid - The Angeles Clinic, California, USA
Combination of MEDI0680, an anti-PD-1 antibody, with durvalumab, an anti-PD-L1 antibody: ( Dr Omid Hamid - The Angeles Clinic, California, USA )
12 Oct 2016
LUME study of nintedanib finds improved PFS, but no overall survival boost
Prof Eric Van Cutsem - University of Leuven, Leuven, Belgium
LUME study of nintedanib finds improved PFS, but no overall survival boost ( Prof Eric Van Cutsem - University of Leuven, Leuven, Belgium )
12 Oct 2016
Left versus right sided GI tumour response in the CRYSTAL trial
Prof Eric Van Cutsem - University of Leuven, Leuven, Belgium
Left versus right sided GI tumour response in the CRYSTAL trial ( Prof Eric Van Cutsem - University of Leuven, Leuven, Belgium )
10 Oct 2016
Oncolytic virotherapy using coxsackie virus
Dr Hardev Pandha - University of Surrey, Guildford, UK
Oncolytic virotherapy using coxsackie virus ( Dr Hardev Pandha - University of Surrey, Guildford, UK )
10 Oct 2016
Results of the Activ8 trial of novel immunotherapy motolimod
Dr Ezra Cohen - UC San Diego, San Diego, USA
Results of the Activ8 trial of novel immunotherapy motolimod ( Dr Ezra Cohen - UC San Diego, San Diego, USA )
10 Oct 2016
Lurbinectedin in PARP resistant breast cancer
Dr Cristina Cruz - Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain
Lurbinectedin in PARP resistant breast cancer ( Dr Cristina Cruz - Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain )
10 Oct 2016
Lurbinectedin in BRCA 1/2 breast cancer
Dr Judith Balmaña - Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain
Lurbinectedin in BRCA 1/2 breast cancer ( Dr Judith Balmaña - Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain )
10 Oct 2016
Treating CNS metastases from breast cancer with a peptide/paclitaxel conjugate
Prof Shou-Ching Tang - Augusta University Cancer Center, Augusta USA
Treating CNS metastases from breast cancer with a peptide/paclitaxel conjugate ( Prof Shou-Ching Tang - Augusta University Cancer Center, Augusta USA )
10 Oct 2016
Highlights of ESMO 2016
Dr Andrés Cervantes - ESMO 2016 Scientific Chair
Highlights of ESMO 2016 ( Dr Andrés Cervantes - ESMO 2016 Scientific Chair )
10 Oct 2016
Adjuvant sunitinib for renal cell carcinoma
Dr Alain Ravaud - Centre Hospitalier Universitaire de Bordeaux, Bordeaux, France
Adjuvant sunitinib for renal cell carcinoma ( Dr Alain Ravaud - Centre Hospitalier Universitaire de Bordeaux, Bordeaux, France )
10 Oct 2016
Longer disease-free survival in phase III trial of sunitinib as adjuvant...
Dr Alain Ravaud - Centre Hospitalier Universitaire de Bordeaux, Bordeaux, France
Longer disease-free survival in phase III trial of sunitinib as adjuvant treatment for kidney cancer ( Dr Alain Ravaud - Centre Hospitalier Universitaire de Bordeaux, Bordeaux, France )
10 Oct 2016

More from ecancer

Register with ecancer to receive our newsletter

Register here

Explore patient resources at ecancerpatient

Visit site

Find out more about ecancer and the work we do

About ecancer

Support ecancer's work by making a donation